SCHEMBL21580801

SCHEMBL21580801

CCOC(=O)c1ccc2ccc(C3(Br)CC3)cn2c1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 8/20 0.42
▸ GLA P06280 4/20 0.42
▸ GAA P10253 4/20 0.42
▸ ALDH1A1 P00352 6/20 0.41
▸ HPGD P15428 4/20 0.41
▸ HSD17B10 Q99714 4/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ TP53 P04637 1/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ NPSR1 Q6W5P4 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ TSHR P16473 1/20 0.38
▸ RECQL P46063 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.37
▸ CA12 O43570 1/20 0.36
▸ CA1 P00915 1/20 0.36
▸ CA2 P00918 1/20 0.36
▸ CA7 P43166 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13316524 0.79 LMNA (0.47) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10361540 0.79 KDM4E (0.63) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10362961 0.78 KDM4E (0.48) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL7222086 0.78 CA12 (0.53) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL21580872 0.77 CYP4F2 (0.50) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL21580790 0.77 KDM4E (0.45) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL25085840 0.77 KDM4E (0.47) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10362966 0.76 KDM4E (0.46) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10361674 0.72 KDM4E (0.43) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL10362968 0.72 KDM4E (0.46) KDM4EGLAGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3802549-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. Hoffmann-La Roche AG (CH) 2021-04-14 — — EP disclosed
WO-2019228940-A1 NOVEL OXOQUINOLIZINE COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF BACTERIAL INFECTION F. HOFFMANN-LA ROCHE AG (CH) 2019-12-05 — — WO disclosed
Send feedback